Guardant Health, Pfizer Collaborate To Develop New Cancer Therapies Using Liquid Biopsy Platform

Guardant Health, Inc. GH on Thursday announced a strategic collaboration with Pfizer, Inc. PFE to support the development and commercialization of Pfizer’s oncology portfolio using the Guardant Infinity smart liquid biopsy platform.

Under the multi-year collaboration agreement, Guardant and Pfizer aim to:

Utilize Guardant’s portfolio of liquid biopsy tests in Pfizer’s global clinical studies.
Evaluate the clinical utility of (a) circulating tumor DNA (ctDNA) level as a surrogate endpoint to monitor therapy response and (b) related blood-based epigenomic analyses.

Also Read: Medicare To Reimburse Guardant Health’s Shield Colorectal Cancer Test, Analyst Expects $10M In Revenue

The collaboration will also allow Pfizer to access Guardant’s liquid biopsy tests in China for its global clinical trials, which include China cohorts.

In July 2022, Guardant announced a strategic partnership with Adicon Holdings Limited, an independent clinical laboratory company based in China, to offer Guardant tests to biopharmaceutical companies conducting clinical trials in China.

In January, Guardant Health announced that Palmetto GBA, a Medicare administrative contractor that administers the Molecular Diagnostics Services program (MolDX), granted coverage for the Guardant Reveal test to monitor for disease recurrence in patients with colorectal cancer (CRC) following curative intent therapy.

Guardant Reveal, which runs on Guardant’s Smart Liquid Biopsy platform, is a blood test that uses epigenomic (methylation) analysis to detect circulating tumor DNA (ctDNA), a marker of minimal residual disease (MRD). This test predicts cancer recurrence, helping to guide clinical decisions after surgery or chemotherapy.

Price Action: GH stock is up 2.59% at $46.82 at the last check Thursday.

Read Next: